CAR-T is a personalized immunotherapy made from a patient’s white blood cells. The blood cells are removed from the patient and then modified with chimeric antigen receptors (CARs) so they can attack specific proteins. The cells are then infused back into the patient in the hospital.
CAR-T therapy has been approved for treating certain types of blood cancers. Clinical trials are now underway to see if it will be effective in treating metastatic breast cancer. You can find the breast cancer CAR-T trials now enrolling patients below.
CAR-T Therapy: An Overview
- Cancer.gov: Engineering Patients’ Immune Cells to Treat Their Cancers
- Dr. Susan Love Research Foundation (animated video): Impatient Science: CAR-T Cell Immunotherapy
- Cancer Support Community: Frankly Speaking About Cancer: CAR-T Cell Therapies
- CURE Today: Immunotherapy 101: What Patients Can Expect from CAR-T Cell Therapy
CAR-T Therapy: Challenges and Opportunities
- Frontiers in Oncology: CAR-T Immunotherapy: Translation to Solid Tumors
Current CAR-T Trials:
- Hematology/Oncology Today: CAR-T Trial for Metastatic HER2+ Breast Cancer
- Cancer Therapy Advisor: CAR-T Trial for Triple Negative Breast Cancer Underway
- Metastatic Trial Search: Metastatic breast cancer CAR-T trials now enrolling patients
Last Modified on February 24, 2021